News|Articles|May 1, 2013
Principal Investigators Take the Lead FDA-Regulated Studies
Tufts CSDD
Advertisement
The total number of active principal investigators (PIs) participating in FDA-regulated studies worldwide has reached a record high of 27,924 due to rising clinical trial volume and more individual sites conducting fewer trials each year. More than half (53%) of all FDA-regulated clinical trials are now conducted by independent, community based PIs—the first time this segment has taken the leading proportion globally. University, hospital, and government clinics have been gradually losing their market share—falling from about two-thirds of all global FDA-regulated investigators in 2006 to less than half (47%) of the total in 2012.
Figure 1. The percentage of community-based investigators is growing worldwide.
—Tufts Center for the Study of Drug Development, https://csdd.tufts.edu .
Articles in this issue
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
- How ClinOps Teams Should Evaluate GenAI Tools in Trial Discovery
September 11th 2025
- How Recent Policy Changes Could Impact Clinical Research
September 10th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial
2
How Recent Policy Changes Could Impact Clinical Research
3
How ClinOps Teams Should Evaluate GenAI Tools in Trial Discovery
4
FDA Fast Tracks Sanofi’s Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration
5